IgA Nephropathy

Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).

A systematic evaluation compared the incidence of IgAN and changes in its pathology before and during the COVID-19 pandemic.

Researchers wanted to understand kidney changes with O. felineus infection and whether there is an association with IgAN.

A teen who presented with nephrotic syndrome was diagnosed with both dense deposit disease and IgA nephropathy.

Researchers reported the progression of kidney function throughout the course of IgA nephropathy.

Are immunosuppressive therapies used to treat glomerular disease are related to higher cardiovascular risks?

Interim APPLAUSE-IgAN data showed that iptacopan was superior to placebo at reducing proteinuria at nine months.

A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.

Zigakibart for treatment of IgA nephropathy (IgAN) was well tolerated, reduced proteinuria, and stabilized eGFR at 76 weeks.

Researchers reported data from APPLAUSE-IgAN assessing the effects of iptacopan on proteinuria at nine months.

Knowledge Hubs